» Articles » PMID: 20190787

Membrane Transporters in Drug Development

Abstract

Membrane transporters can be major determinants of the pharmacokinetic, safety and efficacy profiles of drugs. This presents several key questions for drug development, including which transporters are clinically important in drug absorption and disposition, and which in vitro methods are suitable for studying drug interactions with these transporters. In addition, what criteria should trigger follow-up clinical studies, and which clinical studies should be conducted if needed. In this article, we provide the recommendations of the International Transporter Consortium on these issues, and present decision trees that are intended to help guide clinical studies on the currently recognized most important drug transporter interactions. The recommendations are generally intended to support clinical development and filing of a new drug application. Overall, it is advised that the timing of transporter investigations should be driven by efficacy, safety and clinical trial enrolment questions (for example, exclusion and inclusion criteria), as well as a need for further understanding of the absorption, distribution, metabolism and excretion properties of the drug molecule, and information required for drug labelling.

Citing Articles

MONSTROUS: a web-based chemical-transporter interaction profiler.

AbdulHameed M, Dey S, Xu Z, Clancy B, Desai V, Wallqvist A Front Pharmacol. 2025; 16:1498945.

PMID: 40078284 PMC: 11896873. DOI: 10.3389/fphar.2025.1498945.


Human and rat renal proximal tubule in vitro models for ADME applications.

Klatt O, de Brouwer L, Hendriks F, Dehne E, Atac Wagegg B, Jennings P Arch Toxicol. 2025; .

PMID: 40032686 DOI: 10.1007/s00204-025-03987-4.


Structures and membrane interactions of human OAT1 in complex with clinical used drugs.

Wu X, Luo Y, Feng S, Ma H, Ke B, Wang K Sci Adv. 2025; 11(7):eads5405.

PMID: 39951534 PMC: 11827633. DOI: 10.1126/sciadv.ads5405.


Investigating the role of exosomal long non-coding RNAs in drug resistance within female reproductive system cancers.

Shirani N, Abdi N, Chehelgerdi M, Yaghoobi H, Chehelgerdi M Front Cell Dev Biol. 2025; 13:1485422.

PMID: 39925739 PMC: 11802832. DOI: 10.3389/fcell.2025.1485422.


Effect of probenecid on the whole-body disposition of 6-bromo-7-[C]methylpurine in humans assessed with long axial field-of-view PET/CT.

Jackwerth M, Mairinger S, Rausch I, Weber M, Jorda A, Nics L Eur J Nucl Med Mol Imaging. 2025; .

PMID: 39920267 DOI: 10.1007/s00259-025-07121-5.


References
1.
Shu Y, Sheardown S, Brown C, Owen R, Zhang S, Castro R . Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest. 2007; 117(5):1422-31. PMC: 1857259. DOI: 10.1172/JCI30558. View

2.
Yue W, Abe K, Brouwer K . Knocking down breast cancer resistance protein (Bcrp) by adenoviral vector-mediated RNA interference (RNAi) in sandwich-cultured rat hepatocytes: a novel tool to assess the contribution of Bcrp to drug biliary excretion. Mol Pharm. 2008; 6(1):134-43. PMC: 3135650. DOI: 10.1021/mp800100e. View

3.
Matsson P, Englund G, Ahlin G, Bergstrom C, Norinder U, Artursson P . A global drug inhibition pattern for the human ATP-binding cassette transporter breast cancer resistance protein (ABCG2). J Pharmacol Exp Ther. 2007; 323(1):19-30. DOI: 10.1124/jpet.107.124768. View

4.
Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T . Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther. 2003; 73(6):554-65. DOI: 10.1016/S0009-9236(03)00060-2. View

5.
Jonker J, Wagenaar E, Van Eijl S, Schinkel A . Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations. Mol Cell Biol. 2003; 23(21):7902-8. PMC: 207626. DOI: 10.1128/MCB.23.21.7902-7908.2003. View